Taris Biomedical LLC

ACTIVE

113 Hartwell Ave, 马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.tarisbiomedical.comSubsidiary11–50 employeesEstablished: 2008-01-01

Part of 强生

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2008

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

71.4%

Trial Status Distribution

Completed

85.7%

Terminated

14.3%

Clinical Trials

Trials sponsored by this organization (7)

Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

Phase 1

Terminated

interventional

Jan 201913 participants

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

Phase 1

Completed

interventional

Apr 20177 participants

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

Phase 1

Completed

interventional

Apr 201743 participants

Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

Phase 1

Completed

interventional

May 201623 participants

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

Phase 1

Completed

interventional

Jan 201612 participants

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects with Muscle-Invasive Transitional Cell Carcinoma of the Bladder

Completed

interventional

6 participants

A phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225mg in Subjects with Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Completed

interventional

30 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations